Use of Defibrotide in Patients with COVID-19 Pneumonia; Results of the Defi-VID19 Phase 2 Trial

Background: The clinical spectrum of COVID-19 ranges from pauci-symptomatic forms to severe disease characterized by respiratory failure requiring mechanical ventilation and intensive care unit (ICU) management, as well as multisystem involvement characterized by sepsis, organ dysfunction and death....

Descripción completa

Detalles Bibliográficos
Autores principales: Ruggeri, Annalisa, Voza, Antonio, Liberatore, Carmine, Catalano, Gloria, Corrado, Francesco, Di Filippo, Luigi, Nitti, Rosamaria, Fedeli, Carlo, Bruno, Alessandro, Calabretta, Eleonora, Giglio, Fabio, Sciutti, Fabio, Lunghi, Francesca, Landoni, Giovanni, Richardson, Paul G., Iacobelli, Massimo, Aghemo, Alessio, Rovere-Querini, Patrizia, Assanelli, Andrea A., Peccatori, Jacopo, Ciceri, Fabio, Carlo-Stella, Carmelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
332.Anticoagulation and Antithrombotic Therapies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701766/
http://dx.doi.org/10.1182/blood-2021-147784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701766/
http://dx.doi.org/10.1182/blood-2021-147784

Ejemplares similares